Literature DB >> 32418080

ASO Author Reflections: Predictors of Fiscal Outcomes in CRS-HIPEC and Opportunities for Improvement.

Patrick B Schwartz1, Daniel E Abbott2.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32418080     DOI： 10.1245/s10434-020-08598-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  4 in total

Review 1.  Pseudomyxoma peritonei syndrome.

Authors:  P H Sugarbaker; B M Ronnett; A Archer; A M Averbach; R Bland; D Chang; R R Dalton; S E Ettinghausen; P Jacquet; J Jelinek; P Koslowe; R J Kurman; B Shmookler; A D Stephens; M A Steves; O A Stuart; S White; C M Zahn; F A Zoetmulder
Journal:  Adv Surg       Date:  1996

2.  Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost-utility analysis of a hospital's initial experience and reflections on the health care system.

Authors:  Samer A Naffouje; Cristina O'Donoghue; George I Salti
Journal:  J Surg Oncol       Date:  2016-01-11       Impact factor: 3.454

3.  Implementation of an Enhanced Recovery After Surgery (ERAS) Program is Associated with Improved Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Christopher Webb; Ryan Day; Cristine S Velazco; Barbara A Pockaj; Richard J Gray; Chee-Chee Stucky; Tonia Young-Fadok; Nabil Wasif
Journal:  Ann Surg Oncol       Date:  2019-10-11       Impact factor: 5.344

4.  Association between hospital finances, payer mix, and complications after hyperthermic intraperitoneal chemotherapy: deficiencies in the current healthcare reimbursement system and future implications.

Authors:  Malcolm H Squires; Christopher A Staley; William Knechtle; Joshua H Winer; Maria C Russell; Sebastian Perez; John F Sweeney; Shishir K Maithel; Charles A Staley
Journal:  Ann Surg Oncol       Date:  2014-09-24       Impact factor: 5.344
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.